CD8+ CD28− regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study-Reference-Cited by-同舟云学术

CD8+ CD28− regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study

Published:2024-06-03 Issue:7 Volume:38 Page:1621-1625
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Kriegsmann Katharina,Ton Gigi Nu Hoang Quy,Awwad Mohamed H. S.^ORCID,Benner Axel,Bertsch Uta,Besemer Britta,Hänel Mathias,Fenk Roland,Munder Markus,Dürig Jan,Blau Igor W.,Huhn Stefanie,Hose Dirk,Jauch Anna,Mann Christoph,Weinhold Niels^ORCID,Scheid Christof,Schroers Roland^ORCID,von Metzler Ivana,Schieferdecker Aneta,Thomalla Jörg,Reimer Peter,Mahlberg Rolf,Graeven Ullrich^ORCID,Kremers Stephan,Martens Uwe M.,Kunz Christian,Hensel Manfred,Seidel-Glätzer Andrea,Weisel Katja C.^ORCID,Salwender Hans J.^ORCID,Müller-Tidow Carsten^ORCID,Raab Marc S.^ORCID,Goldschmidt Hartmut,Mai Elias K.^ORCID,Hundemer Michael^ORCID

Funder

Bristol-Myers Squibb

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41375-024-02290-y.pdf

Reference15 articles.

1. Dhodapkar MV, Krasovsky J, Olson K. T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells. Proc Natl Acad Sci USA. 2002;99:13009–13.

2. Muthu Raja KR, Rihova L, Zahradova L, Klincova M, Penka M, Hajek R. Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma. PloS One. 2012;7:e47077.

3. Collins SM, Bakan CE, Swartzel GD, Hofmeister CC, Efebera YA, Kwon H, et al. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunol, Immunother. 2013;62:1841–9.

4. Pazina T, James AM, Colby KB, Yang Y, Gale A, Jhatakia A, et al. Enhanced SLAMF7 homotypic interactions by elotuzumab improves NKcell killing of multiple myeloma. Cancer Immunol Res. 2019;7:1633–46.

5. MHS Awwad, A Mahmoud, H Bruns, H Echchannaoui, K Kriegsmann, R Lutz et al. Selective elimination of immunosuppressive T cells in patients with multiple myeloma. Leukemia. 2021;35:2602–2615.